Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling

Cardiovascular Research

Volumn 46, Issue 2, 2000, Pages 214-224

  Li, Yun You ^a   McTiernan, Charles F ^a   Feldman, Arthur M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Extracellular matrix; Fibrosis; Gene therapy; Heart failure; Remodeling

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FIBROBLAST; GENE THERAPY; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ANIMALS; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; GENE THERAPY; HEART DISEASES; HUMANS; MATRIX METALLOPROTEINASES; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR REMODELING;

EID: 0034115114     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00003-1     Document Type: Review

References (102)

1. Vincenti M.P., White L.A., Schroen D.J., Benbow U., Brinckerhoff C.E. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryotic Gene Expr. 6:1996;391-411.
2. Dollery C.M., McEwan J.R., Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res. 77:1995;863-868.
3. Gutman A., Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J. 9:1990;2241-2246.
4. Auble D.T., Brinckerhoff C.E. The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts. Biochemistry. 30:1991;4629-4635.
5. Halazonetis T.D., Georgopoulos K., Greenberg M.E., Leder P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell. 55:1988;917-924.
6. Gum R., Lengyel E., Juarez J., et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 271:1996;10672-10680.
7. Brenner D.A., O'Hara M., Angel P., Chojkier M., Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature. 337:1989;661-663.
8. Conca W., Kaplan P.B., Krane S.M. Increases in levels of procollagenase mRNA in human fibroblasts induced by interleukin-1, tumor necrosis factor-alpha, or serum follow c-jun expression and are dependent on new protein synthesis. Trans Assoc Am Physicians. 102:1989;195-203.
9. Li Y.Y., McTiernan C.F., Feldman A.M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res. 42:1999;162-172.
10. Delany A.M., Brinckerhoff C.E. Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts. J Cell Biochem. 50:1992;400-410.
11. Duivenvoorden W.C., Hirte H.W., Singh G. Transforming growth factor beta 1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 17:1999;27-34.
12. Wahl S.M., Allen J.B., Weeks B.S., Wong H.L., Klotman P.E. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA. 90:1993;4577-4581.
13. Edwards D.R., Leco K.J., Beaudry P.P., et al. Differential effects of transforming growth factor-beta 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Exp Gerontol. 31:1996;207-223.
14. Kleiner D.E. Jr., Tuuttila A., Tryggvason K., Stetler-Stevenson W.G. Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry. 32:1993;1583-1592.
15. Yu A.E., Murphy A.N., Stetler-Stevenson W.G. 72-kDa Gelatinase (gelatinase A): structure, activation, regulation, and substrate specificity. Parks W.C., Mecham R.P. Matrix metalloproteinases. 1998;357 Academic Press, San Diego.
16. Mertens P.R., Alfonso-Jaume M.A., Steinmann K., Lovett D.H. A synergistic interaction of transcription factors AP-2 and YB-1 regulates gelatinase A enhancer-dependent transcription. J Biol Chem. 273:1998;32957-32965.
17. Biswas C., Zhang Y., DeCastro R., et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 55:1995;434-439.
18. Guo H., Zucker S., Gordon M.K., Toole B.P., Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem. 272:1997;24-27.
19. Lim M., Martinez T., Jablons D., et al. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 441:1998;88-92.
20. Thomas C.V., Coker M.L., Zellner J.L., et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 97:1998;1708-1715.
21. Li Y.Y., Feldman A.M., Sun Y., McTiernan C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 98:1998;1728-1734.
22. Li Y.Y., McTiernan C.F., Moravec C.S., Kormos R.L., Feldman A.M. The activated matrix metalloproteinase-9 in the failing human heart is suppressed by LVAD support. Circulation. 100:(Suppl I):1999;I560.
23. Tyagi S.C., Lewis K., Pikes D., et al. Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells. J Cell Physiol. 176:1998;374-382.
24. Chesler N.C., Ku D.N., Galis Z.S. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol. 277:1999;H2002-H2009.
25. Vu T.H., Werb Z. Gelatinase B: structure, regulation, and function. Parks W.C., Mecham R.P. Matrix metalloproteinases. 1998;115-148 Academic Press, San Diego.
26. Corcoran M.L., Kibbey M.C., Kleinman H.K., Wahl L.M. Laminin SIKVAV peptide induction of monocyte/macrophage prostaglandin E2 and matrix metalloproteinases. J Biol Chem. 270:1995;10365-10368.
27. Huhtala P., Humphries M.J., McCarthy J.B., et al. Cooperative signaling by alpha 5 beta 1 and alpha 4 beta 1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol. 129:1995;867-879.
28. Tremble P., Chiquet-Ehrismann R., Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell. 5:1994;439-453.
29. Lijnen H.R., Lupu F., Moons L., et al. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost. 81:1999;799-807.
30. Olson M.W., Toth M., Gervasi D.C., et al. High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. J Biol Chem. 273:1998;10672-10681.
31. Makela M., Salo T., Larjava H. MMP-9 from TNF alpha-stimulated keratinocytes binds to cell membranes and type I collagen: a cause for extended matrix degradation in inflammation? Biochem Biophys Res Commun. 253:1998;325-335.
32. Nguyen M., Arkell J., Jackson C.J. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem. 273:1998;5400-5404.
33. Lijnen H.R., Silence J., Lemmens G., Frederix L., Collen D. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb Haemost. 79:1998;1171-1176.
34. Sperti G., van Leeuwen R.T., Quax P.H., Maseri A., Kluft C. Cultured rat aortic vascular smooth muscle cells digest naturally produced extracellular matrix. Involvement of plasminogen-dependent and plasminogen-independent pathways. Circ Res. 71:1992;385-392.
35. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 274:1999;13066-13076.
36. Knauper V., Murphy G. Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases. Parks W.C., Mecham R.P. Matrix metalloproteinases. 1998;357 Academic Press, San Diego.
37. Tyagi S.C., Kumar S.G., Alla S.R., et al. Extracellular matrix regulation of metalloproteinase and antiproteinase in human heart fibroblast cells. J Cell Physiol. 167:1996;137-147.
38. Ravanti L., Heino J., Lopez-Otin C., Kahari V.M. Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J Biol Chem. 274:1999;2446-2455.
39. Wesley R.B. 2nd., Meng X., Godin D., Galis Z.S. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol. 18:1998;432-440.
40. Theret N., Lehti K., Musso O., Clement B. MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology. 30:1999;462-468.
41. Woessner J.F. Jr. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann New York Acad Sci. 878:1999;388-403.
42. Johnson M.D., Kim H.R., Chesler L., et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol. 160:1994;194-202.
43. Bertaux B., Hornebeck W., Eisen A.Z., Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol. 97:1991;679-685.
44. Greenwald R.A. Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought? Ann New York Acad Sci. 878:1999;413-419.
45. Tyagi S.C., Campbell S.E., Reddy H.K., Tjahja E., Voelker D.J. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 155:1996;13-21.
46. Spinale F.G., Coker M.L., Krombach S.R., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 85:1999;364-376.
47. Skotnicki J.S., Zask A., Nelson F.C., Albright J.D., Levin J.I. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann New York Acad Sci. 878:1999;61-72.
48. Golub L.M., Ramamurthy N.S., Llavaneras A., et al. A chemically modified nonantimicrobial tetracycline (CMT-8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats. Ann New York Acad Sci. 878:1999;290-310.
49. Forough R., Koyama N., Hasenstab D., et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 79:1996;812-820.
50. Dollery C.M., Humphries S.E., McClelland A., Latchman D.S., McEwan J.R. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation. 99:1999;3199-3205.
51. Baker A.H., Zaltsman A.B., George S.J., Newby A.C. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 101:1998;1478-1487.
52. Allaire E., Forough R., Clowes M., Starcher B., Clowes A.W. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest. 102:1998;1413-1420.
53. George S.J., Baker A.H., Angelini G.D., Newby A.C. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 5:1998;1552-1560.
54. Cheng L., Mantile G., Pauly R., et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation. 98:1998;2195-2201.
55. Greene J., Wang M., Liu Y.E., et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 271:1996;30375-30380.
56. Dollery C.M., McEwan J.R., Wang M., et al. TIMP-4 is regulated by vascular injury in rats. Circ Res. 84:1999;498-504.
57. Shapiro S.D. Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function. Matrix Biol. 15:1997;527-533.
58. Rudolph-Owen L.A., Cannon P., Matrisian L.M. Overexpression of the matrix metalloproteinase matrilysin results in premature mammary gland differentiation and male infertility. Mol Biol Cell. 9:1998;421-435.
59. Sympson C.J., Talhouk R.S., Alexander C.M., et al. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol. 125:1994;681-693.
60. D'Armiento J.M., Kim H.E., O'Byrne T.K., et al. Myocardial overexpression of collagenase in the transgenic mouse produces left ventricular hypertrophy and hypercontractility. Circulation. 96:(8S):1997;I520.
61. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 81:1997;627-635.
62. Vu T.H., Shipley J.M., Bergers G., et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:1998;411-422.
63. Heymans S., Luttun A., Nuyens D., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure [see comments]. Nat Med. 5:1999;1135-1142.
64. Moons L., Shi C., Ploplis V., et al. Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest. 102:1998;1788-1797.
65. Bullard K.M., Mudgett J., Scheuenstuhl H., Hunt T.K., Banda M.J. Stromelysin-1-deficient fibroblasts display impaired contraction in vitro. J Surg Res. 84:1999;31-34.
66. Nothnick W.B., Soloway P., Curry T.E. Jr. Assessment of the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) during the periovulatory period in female mice lacking a functional TIMP-1 gene. Biol Reprod. 56:1997;1181-1188.
67. Roten L.M., Nemoto S., Simsic J.M., et al. Effects of tissue inhibitor of the matrix metalloproteinase-type 1 gene deletion on left ventricular geometry and function. Circulation. 100:(Suppl I):1999;I560.
68. Whittaker P. Unravelling the mysteries of collagen and cicatrix after myocardial infarction. Cardiovasc Res. 29:1995;758-762.
69. Beltrami C.A., Finato N., Rocco M., et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 89:1994;151-163.
70. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol. 13:1989;1637-1652.
71. Chapman D., Weber K.T., Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res. 67:1990;787-794.
72. Weber K.T., Janicki J.S., Shroff S.G., et al. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res. 62:1988;757-765.
73. Bishop J.E., Greenbaum R., Gibson D.G., Yacoub M., Laurent G.J. Enhanced deposition of predominantly type I collagen in myocardial disease. J Mol Cell Cardiol. 22:1990;1157-1165.
74. Mukherjee D., Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest. 88:1991;1141-1146.
75. Bishop J.E., Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res. 42:1999;27-44.
76. Janicki J.S., Matsubara B.B., Kabour A. Myocardial collagen and its functional role. Adv Exp Med Biol. 346:1993;291-298.
77. Norton G.R., Tsotetsi J., Trifunovic B., et al. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation. 96:1997;1991-1998.
78. Gunja-Smith Z., Morales A.R., Romanelli R., Woessner J.F. Jr. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 148:1996;1639-1648.
79. Li Y.Y., Feng Y.Q., Kadokami T., McTiernan C.F., Feldman A.M. Modulation of matrix metalloproteinase activities remodels myocardial extracellular matrix in TNFα transgenic mice. Circulation. 100:(Suppl I):1999;I752.
80. 2+. FEBS Lett. 238:1988;343-346.
81. Taipale J., Keski-Oja J. Growth factors in the extracellular matrix. FASEB J. 11:1997;51-59.
82. Janicki J.S. Collagen degradation in the heart. Eghbali-Webb M. Molecular biology of collagen matrix in the heart. 1995;61-76 Landes, Austin, TX.
83. Cleutjens J.P., Kandala J.C., Guarda E., Guntaka R.V., Weber K.T. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 27:1995;1281-1292.
84. Simeon A., Monier F., Emonard H., et al. Fibroblast-cytokine-extracellular matrix interactions in wound repair. Curr Top Pathol. 93:1999;95-101.
85. Kamoun A., Landeau J.M., Godeau G., et al. Growth stimulation of human skin fibroblasts by elastin-derived peptides. Cell Adhes Commun. 3:1995;273-281.
86. Lopez-Moratalla N., del Mar Calonge M., Lopez-Zabalza M.J., et al. Activation of human lymphomononuclear cells by peptides derived from extracellular matrix proteins. Biochim Biophys Acta. 1265:1995;181-188.
87. Lane T.F., Sage E.H. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J. 8:1994;163-173.
88. Cleutjens J.P., Verluyten M.J., Smiths J.F., Daemen M.J. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 147:1995;325-538.
89. Weber K.T. Extracellular matrix remodeling in heart failure - a role for de novo angiotensin II generation. Circulation. 96:1997;4065-4082.
90. Eghbali M., Tomek R., Sukhatme V.P., Woods C., Bhambi B. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res. 69:1991;483-490.
91. Sun Y., Zhang J.Q., Zhang J., Ramires F.J. Angiotensin II, transforming growth factor-beta 1 and repair in the infarcted heart. J Mol Cell Cardiol. 30:1998;1559-1569.
92. Tomita H., Egashira K., Ohara Y., et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 32:1998;273-279.
93. Villarreal F.J., Lee A.A., Dillmann W.H., Giordano F.J. Adenovirus-mediated overexpression of human transforming growth factor-beta 1 in rat cardiac fibroblasts, myocytes and smooth muscle cells. J Mol Cell Cardiol. 28:1996;735-742.
94. Diaz A., Munoz E., Johnston R., Korn J.H., Jimenez S.A. Regulation of human lung fibroblast alpha 1(I) procollagen gene expression by tumor necrosis factor alpha, interleukin-1 beta, and prostaglandin E2. J Biol Chem. 268:1993;10364-10371.
95. Brilla C.G., Matsubara L., Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension. 28:1996;269-275.
96. Dixon I.M.C., Ju H.S., Reid N.L., et al. Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol. 29:1997;1837-1850.
97. Brown L., Duce B., Miric G., Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol. 10:(Suppl 11):1999;S143-148.
98. Janicki J.S., Brower G.L., Henegar J.R., Wang L. Ventricular remodeling in heart failure: the role of myocardial collagen. Adv Exp Med Biol. 382:1995;239-245.
99. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New Engl J Med. 323:1990;236-241.
100. Lefebvre V., Peeters-Joris C., Vaes G. Production of gelatin-degrading matrix metalloproteinases ("type IV collagenases") and inhibitors by articular chondrocytes during their dedifferentiation by serial subcultures and under stimulation by interleukin-1 and tumor necrosis factor alpha. Biochim Biophys Acta. 1094:1991;8-18.
101. Bozkurt B., Torre-Amione B., Deswal A., et al. Regression of left ventricular remodeling in chronic heart failure after treatment with ENBREL® (Etanercept, p75 TNF receptor Fc fusion protein). Circulation. 100:(Suppl I):1999;I645.
102. Rohde L.E., Ducharme A., Arroyo L.H., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 99:1999;3063-3070.